Tesamorelin for Heart Health: What the Evidence Shows
What human and animal studies show about Tesamorelin for heart health, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 13
- PubMed records, our ledger
- Animal studies
- 0
- PubMed records, our ledger
- Studies we summarised
- 6
- with an outcome for heart health
Evidence for heart health
Each row is an outcome related to heart health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Metabolic effect of VAT response | Tesamorelin patients with an 8% or greater VAT reduction had better triglycerides, adiponectin and glucose homeostasis than nonresponders over 52 weeks. | Human RCT | Clinical infectious diseases 2012, PMID 22495074 |
| VAT, triglycerides and CRP | Tesamorelin reduced visceral fat without changing subcutaneous fat and improved triglycerides, C-reactive protein and carotid intima-media thickness without worsening glucose. | Human RCTn = 60 | The Journal of clinical endocrinology and metabolism 2012, PMID 23015655 |
| VAT and triglycerides at 52 weeks | VAT change was sustained at -18% over 52 weeks, and triglycerides fell 51 mg/dl. | Human RCTn = 410 | AIDS 2008, PMID 18690162 |
| Triglycerides and cholesterol ratio | Triglycerides fell 50 mg/dL with tesamorelin and rose 9 mg/dL with placebo; the total-to-HDL cholesterol ratio fell 0.31 versus a rise of 0.21. | Human RCTn = 412 | The New England journal of medicine 2007, PMID 18057338 |
| Lipids | Triglycerides and the cholesterol-to-HDL ratio fell significantly with 2 mg versus placebo. | Human RCTn = 61 | AIDS 2005, PMID 16052083 |
| Total cholesterol | Total cholesterol improved modestly (mean difference -0.16 mmol/L). | Meta-analysisn = 909 | Journal of the International Association of Providers of AIDS Care 2026, PMID 42538058 |
PubMed records for Tesamorelin and heart health: 13 human, 0 animal (search counts, not studies we reviewed). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Heart disease background
MedlinePlus defines heart disease as a general term covering many types of heart problems, and a type of cardiovascular disease.[7]
Lipids and heart markers in the trials
In the first phase 3 HIV trial, triglycerides fell by 50 mg per deciliter on tesamorelin and rose by 9 on placebo, and the total to HDL cholesterol ratio fell by 0.31 versus a rise of 0.21.[4]
At 52 weeks the triglyceride change was sustained at -51 mg/dl.[3]
A meta-analysis found modest lipid improvements, including total cholesterol lower by 0.16 mmol/L.[6]
In obese adults with reduced GH, C-reactive protein and carotid intima-media thickness (cIMT) also improved.[2]
What the label says about cardiovascular safety
The Egrifta WR label says long-term cardiovascular safety has not been established.[8]
The label also lists fluid retention, including edema, as a warning related to induced GH secretion.[8]
Other peptides people research for heart health
All peptides for heart health, comparedCommon questions
Does Tesamorelin help with heart health?
The strongest study we summarise for heart health is human rct evidence, across 6 studies with an outcome for heart health. A trial result is not an approval; see the legal status.
Is Tesamorelin approved for heart health?
Tesamorelin is FDA approved (Egrifta). Which conditions that approval covers is set by the label; use for anything else is off-label.
What is the best peptide for heart health?
There is no single answer. Our heart health overview compares each candidate by evidence grade and legal status rather than by popularity.
Does tesamorelin lower cholesterol?
In HIV trials it lowered triglycerides and the total to HDL cholesterol ratio, with only modest total cholesterol change in a meta-analysis.[4]
Is tesamorelin safe for the heart?
The label states long-term cardiovascular safety has not been established.[8]
Does tesamorelin affect blood pressure?
No blood pressure outcome is reported in the cached trials, and the label's cardiovascular statement is about long-term safety.[8]
Does tesamorelin raise HbA1c?
The Egrifta WR label reports that more patients on it than on placebo developed diabetes defined by an HbA1c of 6.5% or more: 5% against 1%.[8]
More on Tesamorelin
Sources
- 1Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012PMID 22495074Accessed 2 Oct 2026
- 2Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.The Journal of clinical endocrinology and metabolism · 2012PMID 23015655Accessed 2 Oct 2026
- 3Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.AIDS (London, England) · 2008PMID 18690162Accessed 2 Oct 2026
- 4Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 5A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.AIDS (London, England) · 2005PMID 16052083Accessed 2 Oct 2026
- 6Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.Journal of the International Association of Providers of AIDS Care · 2026PMID 42538058Accessed 2 Oct 2026
- 7Official web pageOfficial web page · web page
- 8EGRIFTA WR prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.